The role of insulin resistance in the development of muscle wasting during cancer cachexia

Journal of Cachexia, Sarcopenia and Muscle

Volumn 3, Issue 1, 2012, Pages 5-11

  Honors, Mary A ^a   Kinzig, Kimberly P ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Animal models; Cancer cachexia; Insulin resistance; Muscle wasting

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CASPASE 3; CLENBUTEROL; GLUCOSE; INSULIN; MESSENGER RNA; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ROSIGLITAZONE; TRANSCRIPTION FACTOR FOXO;

ANOREXIA; CACHEXIA; CANCER MORTALITY; CANCER PATIENT; COLON ADENOCARCINOMA; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; WALKER CARCINOMA; WEIGHT REDUCTION;

EID: 84866540191     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0051-5     Document Type: Review

References (63)

1. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997;89:1763-73.
2. Kolter DP. Cachexia. Ann Intern Med. 2000;133:622-34.
3. Argiles JM, Alvarez B, Lopez-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev. 1997;17:477-98.
4. Tisdale MJ. Wasting in cancer. J Nutr. 1999;129:243S-6S.
5. Baracos VE. Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care. 2002;5:237-9.
6. Gordon JN, Green SR, Goggin PM. Cancer cachexia. Q J Med. 2005;98:779-88.
7. Coats AJS. Treatment goals. In: Hofbauer KG, Anker SD, Inui A, Nicholson JR, editors. Pharmacotherapy of cachexia. Boca Raton, FL: CRC Press; 2006. p. 261-6.
8. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862-71.
9. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002;52:72-91.
10. Winkler MF. Body composition changes in cancer cachexia: are they reversible? Top Clin Nutr. 2004;19:85-94.
11. Mantovani G, Maccios A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs. 2001;61:499-514.
12. Cahill GF, Aoki EE, Brennan MF, Muller WA. Insulin and muscle amino acid balance. Proc Nutr Soc. 1972;31:233-8.
13. Louard RJ, Fryburg DA, Gelfand RA, Barrett EJ. Insulin sensitivity of protein and glucose metabolism in human forearm skeletal muscle. J Clin Invest. 1992;90:2348-54.
14. Gelfand RA, Barrett EJ. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest. 1987;80:1-6.
15. Biolo G, Wolfe RR. Insulin action on protein metabolism. Baillieres Clin Endocrinol Metab. 1993;7:989-1005.
16. Wing SS, The UPS. In diabetes and obesity. BMC Biochem. 2003;9:56.
17. Wang A, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitinproteasome pathway by defects in muscle cell signaling. Endocrinol. 2006;147:4160-8.
18. Price SR, Bailey JL, Wang X, Jurkovitz C, England BK, Ding X, Phillips LS. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent ubiquitin-proteasome proteolytic pathway by a mechanism involving gene transcription. J Clin Invest. 1996;98:1703-8.
19. Mitch WE, Bailey JL, Wang X, Jurkovitz C, Newby D, Price SR. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol Cell Physiol. 1999;276:C1132-8.
20. Hu J, Klein JD, Du J, Wang XH. Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency. Endocrinol. 2008;149:5384-90.
21. Kino T, Mirani M, Alesci S, Chrousos GP. AIDS-related lipodystrophy/ insulin resistance syndrome. HormMetab Res. 2003;35:129-36.
22. Coats AJS, Anker S. Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol. 2000;35:S9-S14.
23. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr. 1999;129:227S-37S.
24. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol. 2006;17:1807-19.
25. Rohdenburg GL, Bernard A, Krehbiel O. Sugar tolerance in cancer. JAMA. 1919;72:1528-30.
26. Glickman AS, Rawson RW. Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer. 1956;9:1127-34.
27. Holroyde CP, Gabuzda TG, Putnam RC, Paul P, Reichard GA. Altered glucose metabolism in metastatic cancer. Cancer Res. 1975;35:3710-4.
28. Jasani B, Donaldson LJ, Ratcliffe JG, Sokhi GS. Mechanism of impaired glucose tolerance in patients with neoplasia. Br J Cancer. 1978;38:287-92.
29. Lundholm K, Holm G, Schersten T. Insulin resistance in patients with cancer. Cancer Res. 1978;38:4665-70.
30. Heber D, Chiebowski RT, Ishibashi DE, Herrold JN, Black JB. Abnormalities in glucose and protein metabolism in noncachectic lung cancer patients. Cancer Res. 1982;42:4815-9.
31. Norton JA, Maher M, Wesley R, White D, Brennan MF. Glucose intolerance in sarcoma patients. Cancer. 1984;54:3022-7.
32. Tayek JA. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr. 1992;11:445-56.
33. Yoshikawa T, Noguchi Y, Doi C, Makino T, Okamoto T, Matsumoto A. Insulin resistance was connected with the alterations of substrate utilization in patients with cancer. Cancer Lett. 1999;141:93-8.
34. Parekh N, Lin Y, Hayes RB, Albu JB, Lu-Yao GL. Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Cause Control. 2010;21:631-42.
35. Guaitani A, Recchia M, Carli M, Rocchetti M, Bartosek I, Garattini S. Walker carcinoma 256: a model for studies on tumorinduced anorexia and cachexia. Oncol. 1982;39:173-8.
36. Fernandes LC, Machado UF, Nogueira CR, Carpinelli AR, Curi R. Insulin secretion in Walker 256 tumor cachexia. Am J Physiol Endocrinol Metab. 1990;258:E1033-6.
37. el Razi Neto SER, Zorn TMT, Curi R, Carpinelli AR. Impairment of insulin secretion in pancreatic islets isolated from Walker 256 tumor-bearing rats. Am J Physiol Cell Physiol. 1996;271:C804-9.
38. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I, Ishitsuka H, Kataoka T, et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 1990;50:2290-5.
39. Asp ML, Tian M, Wendel AA, Belury MA. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer. 2009;126:756-63.
40. Lazarus DD, Destree AT, Mazzola LM, McCormack TA, Dick LR, Xu B, Huang JQ, Pierce JW, et al. A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. Am J Physiol Endocrinol Metab. 1999;277:E332-41.
41. Lundholm K, Korner U, Gunnebo L, Sixt-Ammilon P, Pouladiun M, Daneryd P, Bosaeus I. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res. 2007;13:2699-706.
42. Fernandes LC, Carpinelli AR, Hell NS, Curi R. Improvement of cancer cachexia and decrease ofWalker 256 tumor growth by insulin administration in rats. Cancer Ther Control. 1991;1:259-68.
43. Fernandes LC, Curi R. Reversion of Walker 256 tumor cachexia by insulin treatment: possible mechanisms involved and perspectives for future research. Endocr Relat Cancer. 1997;4:465-74.
44. Piffar PM, Fernandez R, Tchaikovski O, Hirabara SM, Folador A, Pinto GJ, Jakobi S, Gobbo-Bordon D, et al. Naproxen, clenbuterol, and insulin administration ameliorates cancer cachexia and reduce tumor growth in Walker 256 tumor-bearing rats. Cancer Lett. 2003;201:139-48.
45. Moley JF, Morrison SD, Norton JA. Insulin reversal of cancer cachexia in rats. Cancer Res. 1985;45:4925-31.
46. Moley JF, Morrison SD, Gorschboth CM, Norton JA. Body composition changes in rats with experimental cancer cachexia: improvement with exogenous insulin. Cancer Res. 1988;48:2784-7.
47. LazarusDD, Kambayashi T, Lowry SF, Strassmann G. The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-26 mediated cancer cachexia. Cancer Lett. 1996;103:71-7.
48. Komer R, Vrana A. Thiazolidinediones: tools for the research of metabolic syndrome X. Physiol Res. 1998;47:215-25.
49. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Willimason JM, et al. Metformin increased AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002;51:2074-81.
50. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN. Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. Eu J Endocrinol. 2010;162:193-212.
51. Wong AKF, al Zadjali MA, Choy AJ, Lang CC. Insulin resistance: a potential new target for therapy in patients with heart failure. Cardiovasc Ther. 2008;26:203-13.
52. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100:328-41.
53. Diamanti-Kandarakis E, Economou F, Palimeri S, Christakou C. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci. 2010;1205:192-8.
54. Yki-Jarvinen H. Thiazolidinediones. N Engl JMed. 2004;351:1106-18.
55. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes. 2003;52:1943-50.
56. Kintscher U, Law RE. PPARγ-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab. 2005;288:E287-91.
57. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs. 1998;55:675-88.
58. 2-adrenergic agonists in the treatment of muscle atrophy. In: Hofbauer KG, Anker SD, Inui A, Nicholson JR, editors. Pharmacotherapy of cachexia. Boca Raton, FL: CRC Press; 2006. p. 3311-24.
59. 2-adrenergic agonist treatment: possible muscle specific contributions. Life Sci. 2001;69:599-611.
60. Busquet S, Figueras MT, Fuster G, Almendro V, Moore-Carraso R, Ametller E, Argiles JM, Lopez-Soriano FJ. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. 2004;64:6725-31.
61. 2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells. Br J Pharmacol. 2006;147:446-54.
62. Matthael S, Stumvoli M, Kellerer M, Haring H. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 2000;21:585-618.
63. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachex Sarcopenia Muscle. 2010;1:7-8.